Q-omics provides the consensus-scored KRT25 profile across patient tissues and cancer cell-line models. KRT25 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, KRT25 is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, KRT25 RNA expression shows 8,008 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight SKCM, KIRC, and TGCT as cancer lineages where KRT25 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KRT25 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KRT25 survival associations across molecular data types. KRT25 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KRT25 RNA expression–survival associations across cancer types. High KRT25 expression shows unfavorable associations in SKCM, KIRC, KICH, ACC and KIRP, but favorable associations in THYM. The SKCM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for KRT25 RNA expression.
This table summarizes KRT25 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for KRT25. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KRT25 shows lower tumor expression in COAD and higher tumor expression in KIRC, KIRP, UCEC, LUSC and LUAD. The KIRC box plot shows higher KRT25 RNA expression in tumor versus normal tissue (log2 FC = +0.307, t-test p < 0.001).
This table shows molecular features associated with KRT25 in patient tissues and cancer cell lines. In patient samples, KRT25 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, KRT25 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
